OTCMKTS:NGENF NervGen Pharma (NGENF) Stock Price, News & Analysis → How’d you do in 2022 (From Brooks Enterprises) (Ad) Free NGENF Stock Alerts $1.30 -0.05 (-3.70%) (As of 06/5/2024 ET) Add Compare Share Share Today's Range$1.20▼$1.3650-Day Range$1.30▼$1.7252-Week Range$1.16▼$2.99Volume185,690 shsAverage Volume70,579 shsMarket Capitalization$80.30 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get NervGen Pharma alerts: Email Address Ad Brooks EnterprisesWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, was terrible! The majority of market indexes lost over 50% of their value. Almost every day, traders would look at their trading accounts and just see a sea of red.Get those kind of results during the Great Financial Crisis, without having to study more About NervGen Pharma Stock (OTCMKTS:NGENF)NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.Read More NGENF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NGENF Stock News HeadlinesMay 16, 2024 | finance.yahoo.comNervGen Pharma Reports Q1 2024 Financial Results and Operational UpdatesApril 20, 2024 | finance.yahoo.comNervGen Pharma Corp. (NGENF)April 17, 2024 | finance.yahoo.comNervGen Pharma Reports 2023 Year-End Financial Results and Operational UpdatesMarch 28, 2024 | finance.yahoo.comNervGen Completes $23 Million Bought Deal FinancingMarch 22, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - NGENMarch 21, 2024 | finance.yahoo.comNERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERINGFebruary 15, 2024 | finance.yahoo.comNervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord InjuryNovember 9, 2023 | msn.comNervGen Pharma GAAP EPS of -$0.07November 8, 2023 | finance.yahoo.comNeuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on 'Remarkable People' Podcast Hosted by Tech Luminary Guy KawasakiNovember 4, 2023 | morningstar.comNervGen Pharma Corp Ordinary Shares NGENFSeptember 25, 2023 | finance.yahoo.comNervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord InjurySeptember 11, 2023 | finance.yahoo.comNervGen Pharma to Present at 2023 International Spinal Research Trust Network MeetingSeptember 5, 2023 | finance.yahoo.comNervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 22, 2023 | finance.yahoo.comNervGen Pharma to Present on its Drug Candidate NVG-291 and Spinal Cord Injury at Investor ConferenceAugust 8, 2023 | finance.yahoo.comNervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB ApprovalJune 27, 2023 | finance.yahoo.comNervGen Pharma to Receive More than US$3 Million from Wings for Life to Support Upcoming Clinical Study in Spinal Cord InjuryJune 20, 2023 | finance.yahoo.comNervGen Pharma to Present at Upcoming Investor ConferencesMay 15, 2023 | finanznachrichten.deNervGen Pharma Corp.: NervGen Pharma Reports Q1 2023 Results and Provides Operational Update Including Clinical Trials of Proprietary NVG-291May 15, 2023 | finance.yahoo.comNervGen Pharma Reports Q1 2023 Results and Provides Operational Update Including Clinical Trials of Proprietary NVG-291April 14, 2023 | bizjournals.comRaleigh/Durham Pharmaceuticals NewsApril 10, 2023 | finance.yahoo.comNervGen Pharma Appoints Michael Kelly as President & Chief Executive OfficerMarch 30, 2023 | finance.yahoo.comNervGen Pharma Reports 2022 Year End Results and Provides Operational Update Including Plans to Initiate Phase 1b/2a Clinical Trial of Proprietary NVG-291 in Q3 2023March 22, 2023 | ca.finance.yahoo.comNervGen Pharma Corp. (NGEN.V)February 14, 2023 | finance.yahoo.comNervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291January 31, 2023 | seekingalpha.comNGEN:CA NervGen Pharma Corp.See More Headlines Receive NGENF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NervGen Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:NGENF CUSIPN/A CIKN/A WebN/A Phone(778) 731-1711FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,070,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-73.14% Return on Assets-56.59% Debt Debt-to-Equity Ratio0.04 Current Ratio11.21 Quick Ratio11.21 Sales & Book Value Annual Sales$150,000.00 Price / Sales535.34 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares61,770,000Free FloatN/AMarket Cap$80.30 million OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. William Joseph Radvak BASc (Age 61)Co-Founder & Chairman Comp: $165.59kDr. Harold Martin Punnett D.M.D.Co-Founder & Independent DirectorMr. William J. Adams C.A. (Age 62)CPA, CA, CPA, CFO & Corporate Secretary Comp: $276.27kDr. Daniel D. Mikol M.D.Ph.D., Chief Medical OfficerMr. Michael Kelly (Age 58)CEO, President & Director Mr. Brian McAlisterCo-Founder & AdvisorMore ExecutivesKey CompetitorsCybinNYSEAMERICAN:CYBNBiopharmxNYSEAMERICAN:BPMXAmpliphi BiosciencesNYSEAMERICAN:APHBLianBioNASDAQ:LIANBiomXNYSEMKT:PHGEView All Competitors NGENF Stock Analysis - Frequently Asked Questions How have NGENF shares performed in 2024? NervGen Pharma's stock was trading at $2.04 at the beginning of 2024. Since then, NGENF shares have decreased by 36.3% and is now trading at $1.30. View the best growth stocks for 2024 here. Are investors shorting NervGen Pharma? NervGen Pharma saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 276,400 shares, an increase of 301.2% from the April 15th total of 68,900 shares. Based on an average daily trading volume, of 95,200 shares, the short-interest ratio is presently 2.9 days. View NervGen Pharma's Short Interest. How do I buy shares of NervGen Pharma? Shares of NGENF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:NGENF) was last updated on 6/6/2024 by MarketBeat.com Staff From Our Partners"The Biggest Drug Ever" Is ComingUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Phar...Behind the Markets | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC | SponsoredA once-in-a-century investment opportunityIt's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more poten...Stansberry Research | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an eff...Crypto Swap Profits | SponsoredAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NervGen Pharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share NervGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.